ArticleBMC gastroenterology2026
Adherence to the dietary index for gut microbiota and the 5-year incidence of metabolic dysfunction-associated steatotic liver disease in Iranian adults: a prospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiet is a key modulator of gut microbiota and may influence the development of metabolic dysfunction-associated steatotic liver disease (MASLD). The Dietary Index for Gut Microbiota (DI-GM) has been proposed to capture the overall capacity of diet to promote a favorable gut microbial profile. Prospective evidence linking DI-GM to MASLD risk remains limited.
methodsThis prospective analysis included 5,058 adults without MASLD at baseline from the Monitoring of Metabolic Diseases Risk Factors in Tehran (MMRT) study. Dietary intake was assessed using a validated 125-item food frequency questionnaire. The five-year incidence of MASLD was evaluated using multivariable logistic regression models, and associations were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Subgroup analyses were conducted to assess potential effect modification. Sensitivity analyses examined the robustness of results after excluding participants with substantial weight gain and after additional adjustment for metabolic and dietary factors. Mediation analyses were performed to explore potential pathways underlying the observed associations.
resultsOver five years of follow-up, 562 participants developed MASLD. Higher DI-GM scores were associated with a lower likelihood of incident MASLD. In the fully adjusted model, individuals in the highest quartile of DI-GM had 42% lower odds of MASLD compared with those in the lowest quartile (OR:0.58; 95%CI:0.42-0.80; P-trend < 0.01). Each one-standard-deviation increment in DI-GM score was associated with reduced odds of MASLD (OR:0.72; 95%CI:0.65-0.81;P-value < 0.001). The inverse association was more pronounced among women and participants aged ≥ 45 years (P-interaction < 0.01). Mediation analyses suggested that CAP, HOMA-IR, and serum vitamin D partially explained the association.
conclusionsGreater adherence to a diet supportive of gut microbiota, as reflected by higher DI-GM scores, was associated with a lower five-year risk of MASLD. These findings highlight the potential role of microbiota-related dietary patterns in MASLD prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.